The global anti-snoring devices market is projected to grow from USD 0.91 billion in 2024 to USD 1.45 billion by 2029, at a CAGR of 9.8% during the forecast period. Market growth is primarily driven by the increasing prevalence of sleep disorders such as obstructive sleep apnea (OSA), advancements in sleep therapy technologies, and the expanding geriatric population.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215567849
Rising awareness of sleep health, supported by government-led initiatives and public health campaigns, is encouraging early diagnosis and treatment adoption. In addition, technological advancements in oral appliances and improved comfort features are enhancing patient compliance, further supporting market growth. However, high device costs and complex diagnostic pathways may limit adoption to some extent.
Oral Appliances Segment Dominates Market
By device type, oral appliances accounted for the largest share of the anti-snoring devices market in 2023. This dominance is largely attributed to the growing adoption of mandibular advancement devices (MADs), which are widely recognized for their effectiveness in reducing snoring and mild to moderate sleep apnea.
Extensive clinical research supporting their efficacy, along with increasing patient preference for non-invasive treatment options, continues to drive growth in this segment.
Male Segment Holds Largest Share
By gender, the male segment accounted for the largest share of the market in 2023. This is due to a higher prevalence of snoring and obstructive sleep apnea among males, driven by anatomical and physiological differences such as upper airway structure and fat distribution patterns.
These factors contribute to increased demand for anti-snoring solutions among male patients globally.
Ages 40–60 Segment to Register Highest Growth
By age group, individuals between 40 and 60 years are expected to register the highest growth rate during the forecast period. This segment is more prone to conditions such as hypertension, diabetes, and cardiovascular diseases, which are closely associated with sleep disorders.
As awareness increases and diagnosis rates improve, demand for anti-snoring devices among this demographic is expected to rise significantly.
Retail Pharmacies Lead Distribution Channel
By distribution channel, retail pharmacies held the largest share of the market in 2023. Their accessibility, affordability, and convenience make them a preferred purchasing channel for consumers seeking over-the-counter anti-snoring solutions.
Additionally, the growing presence of online pharmacies is expected to complement market expansion by improving product availability and reach.
Homecare Segment Drives End-User Demand
By end user, homecare settings accounted for the largest share of the market in 2023. Increasing patient preference for home-based sleep testing and treatment, along with the availability of advanced home-use devices, is driving growth in this segment.
Homecare solutions offer convenience, cost-effectiveness, and improved patient adherence, making them increasingly popular compared to hospital-based treatments.
Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=215567849
North America Leads Global Market
North America accounted for the largest share of the anti-snoring devices market and is expected to maintain its dominance throughout the forecast period. Growth in the region is driven by the high prevalence of sleep apnea and snoring, along with increasing demand for alternative treatment options due to low adherence to CPAP therapy.
Advanced healthcare infrastructure, strong awareness levels, and the presence of leading market players further support market growth in the region.
Competitive Landscape
Key players operating in the anti-snoring devices market include ResMed (US), SomnoMed (Australia), ProSomnus Sleep Technologies (US), Vivos Therapeutics, Inc. (US), DynaFlex (US), OpenAirway (Canada), Panthera Dental (Canada), Airway Management (US), Apnea Sciences (US), OravanOSA (US), Myerson LLC (US), Braebon Medical Corporation (Canada), MPowrx Health and Wellness Products (Canada), The Snore Reliever Company, LLC (US), Tomed GmbH (Germany), The Aurum Group (Canada), OSCIMED SA (Switzerland), SICAT GmbH & Co. KG (Germany), Glidewell (US), ApnoMed, Inc. (US), and ZQuiet (US), among others.
These companies are focusing on product innovation, patient comfort, and expanding distribution networks to strengthen their position in the global market.
No comments:
Post a Comment